Case Detail

In re Bio-Rad Laboratories, Inc. (2014)


Case Details

  • Case Name
  • In re Bio-Rad Laboratories, Inc. (2014)
  • Date Filed
  • 11/03/2014
  • Enforcement Agency
  • DOJ
  • Countries
  • Russia
  • Foreign Official
  • Russian Ministry of Health Officials.
  • Date of Conduct
  • 2005 to 2010
  • Nature of Business
  • Bio-Rad Laboratories, Inc. is a Delaware corporation headquartered in Hercules, California.  Bio-Rad is a life-science research and clinical diagnostics company with operations in the United States and abroad.  Bio-Rad’s clinical diagnostics segment sells testing kits and systems to clinical laboratories and hospitals, accounting for the majority of the company’s net sales.  Bio-Rad maintains a class of publicly traded securities on the New York Stock Exchange.
  • Influence to be Obtained
  • According to an agreed upon statement of facts, between 2005 and 2010, Bio-Rad’s French subsidiary (“Bio-Rad SNC”), with the assistance of an agent (“Agent 1”), entered into agreements with three offshore companies which purported to provide extensive services for Bio-Rad’s operations in Russia.  Bio-Rad SNC allegedly paid the offshore companies 15-30% commissions for services rendered.  Despite the payments, the statement of facts alleges that the offshore companies had no employees (other than Agent 1) and were incapable of offering the services they agreed to provide in their contracts with Bio-Rad SNC.  
     
    The DOJ alleges that various managers of Bio-Rad SNC approved the agreements with the offshore companies, knowing that it was highly likely portions of the inflated commissions fees were used as bribes.  The managers discussed the contracts with the offshore companies in code and issued payments in amounts under $200,000 to avoid additional internal controls approvals.  As a result of the alleged bribes, Bio-Rad won 100% of the government contracts when Agent 1 was involved and lost its first major contract with the Russian government shortly after Agent 1 had been terminated in 2010.
     
  • Enforcement
  • On November 3, 2014, the DOJ announced that it had entered into a non-prosecution agreement with Bio-Rad to settle charges over violations of the FCPA’s books-and-records and internal controls provisions.  As part of the non-prosecution agreement, Bio-Rad agreed to pay a criminal penalty of $14.3 million.  This criminal penalty was in addition to a $40.7 million sanction in a parallel SEC proceeding for FCPA violations that occurred in Russia, Thailand, and Vietnam.
  • Amount of the Value
  • Not Stated
  • Amount of Business Related to Payment
  • Approximately $35.1 million.
  • Citizenship of Parent Entity
  • United States
  • Total Sanction
  • $ 14,300,000
  • Compliance Monitor
  • No
  • Reporting Requirements
  • Yes
  • Case is Pending?
  • No
  • Total Combined Monetary Sanction
  • $ 55,000,000

Defendants

Bio-Rad Laboratories, Inc. 

  • Citation
  • In re Bio-Rad Laboratories, Inc. (2014).
  • Date Filed
  • 11/03/2014
  • Filed Under Seal
  • No
  • FCPA Statutory Provision
    • Books-and-Records
    • Internal Controls
  • Other Statutory Provision
  • None
  • Disposition
  • Non-Prosecution Agreement
  • Defendant Jurisdictional Basis
  • Issuer
  • Defendant's Citizenship
  • United States
You may share a link to this page on any of the sites listed below:
Material on www.aoshearman.com is general information and should not be construed as legal advice. Contacting us by email does not create a lawyer-client relationship unless and until we have agreed to handle a particular matter. Please do not convey to us any information you regard as confidential unless and until a formal lawyer-client relationship has been established, as any information we receive from you prior to such time will not be confidential.
Accept Cancel